Table 3 Summary of treatment-emergent and treatment-related adverse events by preferred term reported by at least two patients in either treatment group (proof-of-concept component)
Adverse events, number (percentage) | Placebo | Maraviroc 300 mg BID | ||
|---|---|---|---|---|
| Â | Treatment-emergent (n= 33) | Treatment-related (n= 33) | Treatment-emergent (n= 77) | Treatment-related (n= 77) |
Worsening rheumatoid arthritis | 8 (24.2) | 1 (3.0) | 3 (3.9) | 0 |
Constipation | 0 | 0 | 6 (7.8) | 4 (5.2) |
Nausea | 0 | 0 | 4 (5.2) | 3 (3.9) |
Chills | 1 (3.0) | 0 | 2 (2.6) | 2 (2.6) |
Dizziness | 1 (3.0) | 1 (3.0) | 2 (2.6) | 1 (1.3) |
Fatigue | 0 | 0 | 3 (3.9) | 1 (1.3) |
Edema peripheral | 2 (6.1) | 2 (6.1) | 0 | 0 |
Headache | 1 (3.0) | 0 | 2 (2.6) | 1 (1.3) |
Diarrhea | 2 (6.1) | 0 | 1 (1.3) | 1 (1.3) |
Upper respiratory tract infection | 0 | 0 | 3 (3.9) | 0 |
Orthostatic hypotension | 0 | 0 | 2 (2.6) | 1 (1.3) |
Dyspepsia | 0 | 0 | 2 (2.6) | 1 (1.3) |
Pyrexia | 0 | 0 | 2 (2.6) | 1 (1.3) |
Respiratory tract infection | 0 | 0 | 2 (2.6) | 0 |
Influenza | 2 (6.1) | 0 | 0 | 0 |